Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Continued Access to Darunavir/Ritonavir (DRV/Rtv) in HIV-1 Infected Adults, Adolescents and Children Aged 3 Years and Above

NCT01281813 is registered in ClinicalTrials.gov with Janssen Sciences Ireland UC as lead sponsor.

NCT NCT01281813
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01281813 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Continued Access to Darunavir/Ritonavir (DRV/Rtv) in HIV-1 Infected Adults, Adolescents and Children Aged 3 Years and Above
Lead sponsor
Janssen Sciences Ireland UC
Phase
Phase 3
Overall status
Completed
Start date
August 8, 2011
Completion date
July 29, 2021
Enrollment
145 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

hiv-1 infections